GLAXOSMITHKLINE'S Nucala (mepolizumab) is the subject of a new Australian Public Assessment Report (AusPAR) by the Therapeutic Goods Administration as a new biological entity.
Nucala is indicated as an add-on treatment for severe refractory eosinophilic asthma in patients aged 12 years and over.
Access the AusPAR at tga.gov.au.
The above article was sent to subscribers in Pharmacy Daily's issue from 07 Apr 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 07 Apr 17
